Filing summary
Company: Benitec Biopharma Inc. Form: 8-K, dated September 29, 2026; signed September 30, 2026.
Business context and reporting period
The filing reports a change in the Company’s independent registered public accounting firm. It concerns the fiscal year ending June 30, 2027, not a financial-results period.
Auditor engagement
As previously disclosed in a September 24, 2026 Form 8-K, the Company approved engaging Ernst & Young LLP (EY), subject to EY completing client acceptance procedures. EY completed those procedures on September 28, and the Company and EY executed an engagement letter on September 29, 2026.
Financial metrics and comparison
This 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial results, and no comparable-period figures.
Guidance, risks, and unusual items
No guidance, management outlook, contingencies, or financial risks are discussed in the supplied filing text. The reported event is the formal execution of EY’s engagement letter.
Investor verification points
- Review the September 24, 2026 Form 8-K for the earlier disclosure and any additional auditor-transition details.
- The supplied text does not provide details about the predecessor auditor, any disagreements, or any reportable events; consult the complete filing and related disclosures for those details.
- Confirm EY’s appointment applies to the fiscal year ending June 30, 2027.